ES2935605T3 - Combinaciones de cannabinoides y N-aciletanolaminas - Google Patents

Combinaciones de cannabinoides y N-aciletanolaminas Download PDF

Info

Publication number
ES2935605T3
ES2935605T3 ES16786064T ES16786064T ES2935605T3 ES 2935605 T3 ES2935605 T3 ES 2935605T3 ES 16786064 T ES16786064 T ES 16786064T ES 16786064 T ES16786064 T ES 16786064T ES 2935605 T3 ES2935605 T3 ES 2935605T3
Authority
ES
Spain
Prior art keywords
salt
cannabinoid
acylethanolamine
certain embodiments
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16786064T
Other languages
English (en)
Spanish (es)
Inventor
Ascher Shmulewitz
Elran Haber
Ephraim Brener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scisparc Ltd
Original Assignee
Scisparc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scisparc Ltd filed Critical Scisparc Ltd
Application granted granted Critical
Publication of ES2935605T3 publication Critical patent/ES2935605T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
ES16786064T 2015-04-29 2016-04-19 Combinaciones de cannabinoides y N-aciletanolaminas Active ES2935605T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29
PCT/IL2016/050414 WO2016174661A1 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and n-acylethanolamines

Publications (1)

Publication Number Publication Date
ES2935605T3 true ES2935605T3 (es) 2023-03-08

Family

ID=57199061

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16786064T Active ES2935605T3 (es) 2015-04-29 2016-04-19 Combinaciones de cannabinoides y N-aciletanolaminas

Country Status (12)

Country Link
US (7) US11234956B2 (enExample)
EP (2) EP4193993A3 (enExample)
JP (2) JP6938465B2 (enExample)
CN (2) CN107530317A (enExample)
AU (3) AU2016254685B2 (enExample)
CA (1) CA2984088C (enExample)
DK (1) DK3288553T3 (enExample)
ES (1) ES2935605T3 (enExample)
IL (2) IL291864A (enExample)
MA (1) MA41997A (enExample)
PL (1) PL3288553T3 (enExample)
WO (1) WO2016174661A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530317A (zh) * 2015-04-29 2018-01-02 希拉匹克斯生物科学有限公司 大麻素类和n‑酰基乙醇胺的组合
US20210052478A1 (en) * 2018-01-05 2021-02-25 Altus Labs, Llc Personal care compositions
WO2019145783A1 (en) * 2018-01-29 2019-08-01 Therapix Biosciences Ltd. Compositions and methods for treating obstructive sleep apnea
EP3773512A4 (en) * 2018-04-03 2021-12-29 Pure Green, LLC Tablet or composition having n-acyl ethanolamine and cannabinoid
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
AU2020260090C9 (en) * 2019-04-15 2023-08-31 Metagenics LLC Novel hemp and PEA formulation and its use
CA3134885A1 (en) * 2019-04-23 2020-10-29 SciSparc Ltd. Compositions and methods for potentiating derivatives of 4-aminophenols
WO2020227440A1 (en) * 2019-05-07 2020-11-12 Ojai Energetics Pbc Methods for optimized cannabinoid dosage determination
US12491200B2 (en) 2019-05-23 2025-12-09 Igc Pharma Ip, Llc Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of Tourette syndrome
EP4017486A4 (en) * 2019-08-19 2023-09-20 Buzzelet Development And Technologies Ltd COMPOSITIONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND THEIR USES
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US20230080593A1 (en) 2020-01-10 2023-03-16 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
US11918688B2 (en) 2021-01-11 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
US20230000936A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2007006319A2 (en) 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PL2796129T3 (pl) * 2009-09-07 2015-11-30 Epitech Group S P A Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
CN107530317A (zh) * 2015-04-29 2018-01-02 希拉匹克斯生物科学有限公司 大麻素类和n‑酰基乙醇胺的组合

Also Published As

Publication number Publication date
US20180078523A1 (en) 2018-03-22
US11207290B2 (en) 2021-12-28
DK3288553T3 (da) 2023-01-23
US20200038367A1 (en) 2020-02-06
AU2023251426A1 (en) 2023-11-09
IL291864A (en) 2022-06-01
JP6938465B2 (ja) 2021-09-22
US20200022946A1 (en) 2020-01-23
PL3288553T3 (pl) 2023-03-20
AU2016254685A1 (en) 2017-11-09
CA2984088A1 (en) 2016-11-03
AU2023251426B2 (en) 2025-11-27
AU2021206784B2 (en) 2023-07-20
US20210393577A1 (en) 2021-12-23
EP4193993A2 (en) 2023-06-14
US20200030281A1 (en) 2020-01-30
EP4193993A3 (en) 2023-07-19
US20220071949A1 (en) 2022-03-10
MA41997A (fr) 2021-03-31
EP3288553A1 (en) 2018-03-07
WO2016174661A1 (en) 2016-11-03
EP3288553A4 (en) 2018-12-26
IL255238B (en) 2022-05-01
IL255238A0 (en) 2017-12-31
EP3288553B1 (en) 2022-12-28
CN107530317A (zh) 2018-01-02
US20220071948A1 (en) 2022-03-10
US11234956B2 (en) 2022-02-01
US11197845B2 (en) 2021-12-14
CN116549437A (zh) 2023-08-08
JP2021107401A (ja) 2021-07-29
JP2018514589A (ja) 2018-06-07
AU2021206784A1 (en) 2021-08-12
CA2984088C (en) 2024-04-09
AU2016254685B2 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
ES2935605T3 (es) Combinaciones de cannabinoides y N-aciletanolaminas
ES2992838T3 (en) Treatment of irritability in autism spectrum disorder with cannabidiol
EP2943222B1 (en) Solid solution compositions and use in severe pain
ES2985112T3 (es) Composiciones y métodos de potenciación de antimicrobianos
US20170360798A1 (en) Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
ES2344920T3 (es) Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario.
BRPI0712139A2 (pt) uso de agonistas receptores de canabinóide como fármacos indutores de hipotermia para o tratamento da isquemia
US20190380988A1 (en) Anti-inflammatory formulations and uses thereof including a combination of palmitoylethanolamide and plant-based polyphenols
JP2021532171A (ja) カンナビジオールの組み合わせ組成物
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
ES2322148T3 (es) Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
ES2304514T3 (es) Uso de levocetirizina para el tratamiento de rinitis alergica persistente.
ES2363353B1 (es) Composición que comprende gdnf y tgf-beta1 y su uso para el tratamiento de una enfermedad neurológica.
EP4098254A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
RU2744097C2 (ru) Комбинированное противоаллергическое лекарственное средство для назального применения
IT202300009258A1 (it) Nuova associazione di principi attivi, composizioni farmaceutiche e/o nutraceutiche che la contengono e loro uso nella prevenzione e riparazione dei danni del sistema nervoso centrale e periferico
HK40060739A (en) Compositions and methods for potentiating derivatives of 4-aminophenols